Investment objective

To provide long-term capital growth by investing primarily in equity securities of U.S. companies whose businesses relate to life sciences and technology and are expected to benefit from scientific and technological advances.

  • Fund Category U.S. Equity Funds
  • Inception Date Aug 13, 2001
Download fund details    Download fund commentary   

Fund details

Series
Currency
Fund code
MER * (%)
F CAD 35070 0.94%

Portfolio analysis As of Jun 30, 2025

99% 1%
Equity Fixed Income

Asset mix

Equity Sector Allocation
Information Technology58.5%
Communication Services19.1%
Health Care17.8%
Financials2.0%
Industrials1.2%
Consumer Discretionary1.0%
Real Estate0.3%
Top 10 Holdings
% Assets
Microsoft Corp 10.8%
NVIDIA Corp 10.5%
Apple Inc 7.4%
Alphabet Inc - Class A Shares 7.3%
Meta Platforms Inc - Class A Shares 6.5%
Broadcom Inc 5.0%
Eli Lilly & Co 2.7%
Netflix Inc 2.6%
Oracle Corp 1.5%
AbbVie Inc 1.4%
Total % of Top 10 Holdings 55.7%

Geographic allocation

Region

Performance analysis

Growth of $10,000 since inception

Calendar returns

Trailing return

1 Mth 3 Mth 6 Mth 1 year 3 years 5 years 10 years Since Inception
6.8 10.0 0.3 10.1 26.1 16.8 16.4 8.5 Fund

Distribution ($)/unit

YTD* 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Total distributions --- --- --- --- --- --- --- --- --- --- ---
Interest --- --- --- --- --- --- --- --- --- --- ---
Canadian dividends --- --- --- --- --- --- --- --- --- --- ---
Foreign dividends --- --- --- --- --- --- --- --- --- --- ---
Foreign taxes paid --- --- --- --- --- --- --- --- --- --- ---
Capital gains --- --- --- --- --- --- --- --- --- --- ---
Return of capital --- --- --- --- --- --- --- --- --- --- ---

* MER (%) is based on actual expenses for the preceding calendar year or most recent half-year period ended June 30 expressed on an annualized basis, depending on availability of date at the time of publication.